What is Variantyx?
Variantyx operates as a high-growth molecular diagnostics enterprise, specializing in whole-genome sequencing (WGS) to address unmet needs in clinical genetics. The company's core value proposition lies in its ability to provide a holistic view of a patient's genetic profile, moving beyond traditional, fragmented testing methods. By integrating state-of-the-art technology with clinical expertise, Variantyx enables healthcare providers to achieve higher diagnostic yields, particularly in cases where conventional testing has failed to provide clarity. Its market position is reinforced by a commitment to improving patient outcomes through precision medicine, effectively bridging the gap between complex genomic research and routine clinical practice.
How much funding has Variantyx raised?
Variantyx has raised a total of $130.8M across 7 funding rounds:
Series A
$3M
Series B
$10M
Debt
$350K
Series C
$20M
Other Financing Round
$41.5M
Debt
$20M
Private Equity
$36M
Series A (2017): $3M, investors not publicly disclosed
Series B (2019): $10M led by New Era Capital Partners and Pitango Venture Capital
Debt (2020): $350K supported by PPP
Series C (2021): $20M featuring IBM Ventures, Pitango Venture Capital, 20/20 HealthCare Partners, New Era Capital Partners, and GHS Fund
Other Financing Round (2022): $41.5M backed by Rbvc, Peregrine Ventures, 20/20 HealthCare Partners, Pitango Venture Capital, and New Era Capital Partners
Debt (2022): $20M with participation from Kreos Capital Group
Private Equity (2024): $36M led by New Era Capital Partners and Peregrine Ventures
Key Investors in Variantyx
Pitango Venture Capital
Pitango is a prominent venture capital firm that partners with visionary entrepreneurs, supporting groundbreaking companies from stealth mode through to maturity across various healthtech and technology sectors.
Peregrine Ventures
Peregrine Ventures is dedicated to advancing medical innovation through global strategic investments, focusing on life science companies and providing the necessary support to bring healthcare technologies to market.
New Era Capital Partners
New Era Capital Partners is a specialized investment firm operating within the venture capital and private equity landscape, focusing on high-growth opportunities in the technology and life sciences industries.
What's next for Variantyx?
Looking ahead, Variantyx is poised to leverage its recent capital injection to enhance its technological capabilities and broaden its commercial reach. The company's strategic roadmap likely includes the further refinement of its AI-driven diagnostic algorithms and the expansion of its testing portfolio to include new therapeutic areas. As the demand for precision oncology and personalized healthcare solutions continues to rise, Variantyx is well-positioned to capitalize on these trends. By maintaining its focus on clinical excellence and operational efficiency, the firm is set to solidify its role as a critical partner for healthcare systems globally, ultimately driving the next generation of genomic-based diagnostic standards.
See full Variantyx company page
